Fulcrum Therapeutics (FULC) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to 0.92.
- Fulcrum Therapeutics' Equity Ratio rose 11.7% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 11.7%. This contributed to the annual value of 0.93 for FY2024, which is 213.53% up from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Equity Ratio is 0.92, which was up 11.7% from 0.94 recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Equity Ratio peaked at 0.94 during Q1 2025, and registered a low of 0.8 during Q2 2021.
- For the 5-year period, Fulcrum Therapeutics' Equity Ratio averaged around 0.9, with its median value being 0.92 (2023).
- Examining YoY changes over the last 5 years, Fulcrum Therapeutics' Equity Ratio showed a top increase of 2254.63% in 2021 and a maximum decrease of 460.56% in 2021.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Equity Ratio stood at 0.9 in 2021, then decreased by 2.51% to 0.88 in 2022, then rose by 4.0% to 0.91 in 2023, then grew by 2.14% to 0.93 in 2024, then fell by 0.96% to 0.92 in 2025.
- Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.94 for Q2 2025 and 0.94 for Q1 2025.